CVS Health Co. (NYSE:CVS) Shares Acquired by Yousif Capital Management LLC

Yousif Capital Management LLC increased its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 2.8% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 231,834 shares of the pharmacy operator's stock after acquiring an additional 6,207 shares during the period. Yousif Capital Management LLC's holdings in CVS Health were worth $15,707,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CVS. Norges Bank purchased a new position in shares of CVS Health in the fourth quarter valued at $839,574,000. Capital World Investors lifted its holdings in CVS Health by 26.6% in the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after buying an additional 12,819,148 shares in the last quarter. Davis Selected Advisers boosted its position in CVS Health by 2,998.1% in the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after buying an additional 11,018,438 shares during the last quarter. Dodge & Cox grew its stake in shares of CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after acquiring an additional 7,075,209 shares in the last quarter. Finally, Pzena Investment Management LLC increased its position in shares of CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after acquiring an additional 6,475,271 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

CVS stock traded up $0.35 during midday trading on Tuesday, reaching $64.21. The company had a trading volume of 5,529,420 shares, compared to its average volume of 11,033,974. The firm has a market capitalization of $81.22 billion, a PE ratio of 17.54, a P/E/G ratio of 0.98 and a beta of 0.56. The stock has a 50 day moving average price of $65.13 and a 200 day moving average price of $59.98. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 EPS. Analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.14%. CVS Health's dividend payout ratio is currently 63.48%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CVS shares. Argus set a $77.00 price target on CVS Health in a report on Tuesday, February 18th. Robert W. Baird lifted their price target on shares of CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. UBS Group upped their price target on shares of CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday, May 2nd. Leerink Partners raised shares of CVS Health from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $74.75.

Insider Buying and Selling

In other news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction on Thursday, June 5th. The stock was purchased at an average cost of $63.70 per share, with a total value of $100,009.00. Following the purchase, the director now directly owns 12,007 shares of the company's stock, valued at approximately $764,845.90. This trade represents a 15.04% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.22% of the company's stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.